Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Recurrent or Metastatic Head and Neck Cancer
NCT00055913Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2003
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days, Objective Response Rate up to 6 months and 2 more. Started Mar 2003; status: completed.
02
Drugs
bevacizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00055913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055913.